Growing community of inventors

Guangdong, China

Xiumei Lin

Average Co-Inventor Count = 6.95

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 4

Xiumei LinYong Hou (8 patents)Xiumei LinShuntao Luo (8 patents)Xiumei LinTing An (6 patents)Xiumei LinBo Li (4 patents)Xiumei LinBo Li (4 patents)Xiumei LinGeng Liu (3 patents)Xiumei LinGuanglei Li (3 patents)Xiumei LinDongli Li (3 patents)Xiumei LinYing Huang (2 patents)Xiumei LinHandong Li (2 patents)Xiumei LinNaibo Yang (2 patents)Xiumei LinYunxia Tang (2 patents)Xiumei LinChengchi Chao (2 patents)Xiumei LinZhen Cheng (2 patents)Xiumei LinWei Zhang (1 patent)Xiumei LinSi Qiu (1 patent)Xiumei LinChongming Jiang (1 patent)Xiumei LinXiumei Lin (8 patents)Yong HouYong Hou (12 patents)Shuntao LuoShuntao Luo (10 patents)Ting AnTing An (6 patents)Bo LiBo Li (77 patents)Bo LiBo Li (38 patents)Geng LiuGeng Liu (4 patents)Guanglei LiGuanglei Li (3 patents)Dongli LiDongli Li (3 patents)Ying HuangYing Huang (104 patents)Handong LiHandong Li (30 patents)Naibo YangNaibo Yang (5 patents)Yunxia TangYunxia Tang (4 patents)Chengchi ChaoChengchi Chao (2 patents)Zhen ChengZhen Cheng (2 patents)Wei ZhangWei Zhang (64 patents)Si QiuSi Qiu (1 patent)Chongming JiangChongming Jiang (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Genoimmune Therapeutics Co., Ltd. (6 from 7 patents)

2. Bgi Shenzhen (2 from 49 patents)


8 patents:

1. 11834516 - Tumor-specific polypeptide and use thereof

2. 11612643 - Col14A1-derived tumor antigen polypeptide and use thereof

3. 11548925 - CACNA1H-derived tumor antigen polypeptide and use thereof

4. 11466053 - Polypeptide and use thereof

5. 11396528 - Polypeptide and use thereof

6. 11213563 - Polypeptide and use thereof

7. 11161874 - Tumor-specific polypeptide and use thereof

8. 11142547 - Polypeptide and use thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/4/2025
Loading…